Lu AA21004 News
Most Popular Lu AA21004 Story
Lundbeck turns in promising depression data
Lundbeck and its development partner Takeda have announced positive Phase II results for Lu AA21004, a treatment for depression. Study data showed significant improvements on the primary efficacy... Read more...
Latest Headlines
- October 2, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
